1. Pink Sheet
  2. >>Agency Leadership

Next BIO CEO Needs Political Savvy, Greenwood Says

 
• By Derrick Gingery

A scientist may provide a certain look, but understanding politics is more important to ensuring the health of the pharma industry, the outgoing president and CEO of BIO said in an interview.

REGULATION, LAW, RULE_742040296 _1200.jpg
Outgoing BIO CEO Jim Greenwood said the politics of the job takes longer to learn than the science. • Source: Shutterstock

Jim Greenwood's primary requirement for a successor is that they be able to fight bad policy, the one thing that could potentially upset the US's position as a leader in the drug industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By Sue Sutter

Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.